非小细胞肺癌诊断前后恶病质的流行和发展。

IF 1.6 4区 医学 Q4 ONCOLOGY
L Anne Gilmore, Jonas Willmann, Santiago Olaechea, Brian W Gilmore, Edward Christopher Dee, Mihir Rao, Bhavani S Gannavarapu, Shivaek Venkateswaran, Christian M Alvarez, Chul Ahn, Dirk K M de Ruysscher, Urvi A Shah, Neil M Iyengar, Daniel R Gomez, Rodney Infante, Puneeth Iyengar
{"title":"非小细胞肺癌诊断前后恶病质的流行和发展。","authors":"L Anne Gilmore, Jonas Willmann, Santiago Olaechea, Brian W Gilmore, Edward Christopher Dee, Mihir Rao, Bhavani S Gannavarapu, Shivaek Venkateswaran, Christian M Alvarez, Chul Ahn, Dirk K M de Ruysscher, Urvi A Shah, Neil M Iyengar, Daniel R Gomez, Rodney Infante, Puneeth Iyengar","doi":"10.1097/COC.0000000000001211","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Cachexia is commonly defined based on weight loss at the time of cancer diagnosis. However, regular weight measurements before cancer diagnosis are often lacking and may be subject to recall bias if retrospectively self-reported by patients. To analyze the development and progression of cachexia, we employ body weight trajectories from 1 year before and after diagnosis of non-small cell lung cancer (NSCLC). We hypothesized that cachexia could be detected as early as 1 year before NSCLC diagnosis and that cachexia prevalence would increase in the year following diagnosis.</p><p><strong>Methods: </strong>This retrospective study included consecutive patients with NSCLC treated at UTSW between 2005 and 2019 who had body weight measurements before and after NSCLC diagnosis recorded in their electronic health records. Weights were binned in 3-month intervals. Cachexia was defined per the International Consensus Definition of cachexia, that is, loss of >5% body weight 12 months preceding cancer diagnosis for patients with BMI ≥20 kg/m2 or weight loss of >2% for patients with a BMI <20 kg/m2. The association of disease stage and primary treatment with weight changes was investigated.</p><p><strong>Results: </strong>Among 4294 patients screened, 661 patients were included in the final analysis. Patients had a mean age of 69.3 (SD: 10.6) years, and a majority were current/former smokers (83%), identified as white (76%), and were diagnosed with either stage I (47%) or stage IV (28%) nonsquamous NSCLC (78%). At cancer diagnosis, 28% (n=183) presented with cachexia, having incurred a mean loss of 8.6 (SEM: 0.4%) (P<0.0001) of body weight within the year before cancer diagnosis. Weight loss after cancer diagnosis was comparable in patients with and without cachexia at cancer diagnosis (P=0.05). By 12 months postcancer diagnosis, 58% of patients (n=383) met the criteria for cachexia based on weight loss. Weight loss consistent with cachexia occurred over a median period of 220 (IQR: 265) days.</p><p><strong>Conclusion: </strong>Weight loss in patients with cachexia at NSCLC diagnosis may commence as early as 12 months before cancer diagnosis. Within a year after a cancer diagnosis, more than half of patients develop cachexia, particularly those with advanced disease. These findings support the integration of early nutritional and pharmacological interventions in patients with NSCLC.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence and Development of Cachexia Before and After Diagnosis of Non-small Cell Lung Cancer.\",\"authors\":\"L Anne Gilmore, Jonas Willmann, Santiago Olaechea, Brian W Gilmore, Edward Christopher Dee, Mihir Rao, Bhavani S Gannavarapu, Shivaek Venkateswaran, Christian M Alvarez, Chul Ahn, Dirk K M de Ruysscher, Urvi A Shah, Neil M Iyengar, Daniel R Gomez, Rodney Infante, Puneeth Iyengar\",\"doi\":\"10.1097/COC.0000000000001211\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Cachexia is commonly defined based on weight loss at the time of cancer diagnosis. However, regular weight measurements before cancer diagnosis are often lacking and may be subject to recall bias if retrospectively self-reported by patients. To analyze the development and progression of cachexia, we employ body weight trajectories from 1 year before and after diagnosis of non-small cell lung cancer (NSCLC). We hypothesized that cachexia could be detected as early as 1 year before NSCLC diagnosis and that cachexia prevalence would increase in the year following diagnosis.</p><p><strong>Methods: </strong>This retrospective study included consecutive patients with NSCLC treated at UTSW between 2005 and 2019 who had body weight measurements before and after NSCLC diagnosis recorded in their electronic health records. Weights were binned in 3-month intervals. Cachexia was defined per the International Consensus Definition of cachexia, that is, loss of >5% body weight 12 months preceding cancer diagnosis for patients with BMI ≥20 kg/m2 or weight loss of >2% for patients with a BMI <20 kg/m2. The association of disease stage and primary treatment with weight changes was investigated.</p><p><strong>Results: </strong>Among 4294 patients screened, 661 patients were included in the final analysis. Patients had a mean age of 69.3 (SD: 10.6) years, and a majority were current/former smokers (83%), identified as white (76%), and were diagnosed with either stage I (47%) or stage IV (28%) nonsquamous NSCLC (78%). At cancer diagnosis, 28% (n=183) presented with cachexia, having incurred a mean loss of 8.6 (SEM: 0.4%) (P<0.0001) of body weight within the year before cancer diagnosis. Weight loss after cancer diagnosis was comparable in patients with and without cachexia at cancer diagnosis (P=0.05). By 12 months postcancer diagnosis, 58% of patients (n=383) met the criteria for cachexia based on weight loss. Weight loss consistent with cachexia occurred over a median period of 220 (IQR: 265) days.</p><p><strong>Conclusion: </strong>Weight loss in patients with cachexia at NSCLC diagnosis may commence as early as 12 months before cancer diagnosis. Within a year after a cancer diagnosis, more than half of patients develop cachexia, particularly those with advanced disease. These findings support the integration of early nutritional and pharmacological interventions in patients with NSCLC.</p>\",\"PeriodicalId\":50812,\"journal\":{\"name\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COC.0000000000001211\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001211","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:恶病质通常是根据癌症诊断时体重减轻来定义的。然而,在癌症诊断前经常缺乏常规的体重测量,如果患者回顾性地自我报告,可能会受到回忆偏差的影响。为了分析恶病质的发展和进展,我们采用了非小细胞肺癌(NSCLC)诊断前后1年的体重轨迹。我们假设早在NSCLC诊断前1年就可以检测到恶病质,并且在诊断后一年恶病质患病率会增加。方法:本回顾性研究纳入了2005年至2019年期间在UTSW接受治疗的连续非小细胞肺癌患者,这些患者在非小细胞肺癌诊断前后的体重测量记录在其电子健康记录中。每隔3个月将权重分装。恶病质的定义是根据国际共识的恶病质定义,即BMI≥20 kg/m2的患者在癌症诊断前12个月体重减轻> %,BMI≥20 kg/m2的患者体重减轻> %。结果:在筛选的4294例患者中,661例患者被纳入最终分析。患者的平均年龄为69.3岁(SD: 10.6)岁,大多数是现在或以前的吸烟者(83%),白人(76%),诊断为I期(47%)或IV期(28%)非鳞状NSCLC(78%)。在癌症诊断时,28% (n=183)的患者出现恶病质,平均体重下降8.6 (SEM: 0.4%)。结论:在非小细胞肺癌诊断时,患有恶病质的患者体重下降可能早在癌症诊断前12个月就开始了。在癌症诊断后的一年内,超过一半的患者会出现恶病质,尤其是那些病情晚期的患者。这些发现支持NSCLC患者早期营养和药物干预的整合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence and Development of Cachexia Before and After Diagnosis of Non-small Cell Lung Cancer.

Objective: Cachexia is commonly defined based on weight loss at the time of cancer diagnosis. However, regular weight measurements before cancer diagnosis are often lacking and may be subject to recall bias if retrospectively self-reported by patients. To analyze the development and progression of cachexia, we employ body weight trajectories from 1 year before and after diagnosis of non-small cell lung cancer (NSCLC). We hypothesized that cachexia could be detected as early as 1 year before NSCLC diagnosis and that cachexia prevalence would increase in the year following diagnosis.

Methods: This retrospective study included consecutive patients with NSCLC treated at UTSW between 2005 and 2019 who had body weight measurements before and after NSCLC diagnosis recorded in their electronic health records. Weights were binned in 3-month intervals. Cachexia was defined per the International Consensus Definition of cachexia, that is, loss of >5% body weight 12 months preceding cancer diagnosis for patients with BMI ≥20 kg/m2 or weight loss of >2% for patients with a BMI <20 kg/m2. The association of disease stage and primary treatment with weight changes was investigated.

Results: Among 4294 patients screened, 661 patients were included in the final analysis. Patients had a mean age of 69.3 (SD: 10.6) years, and a majority were current/former smokers (83%), identified as white (76%), and were diagnosed with either stage I (47%) or stage IV (28%) nonsquamous NSCLC (78%). At cancer diagnosis, 28% (n=183) presented with cachexia, having incurred a mean loss of 8.6 (SEM: 0.4%) (P<0.0001) of body weight within the year before cancer diagnosis. Weight loss after cancer diagnosis was comparable in patients with and without cachexia at cancer diagnosis (P=0.05). By 12 months postcancer diagnosis, 58% of patients (n=383) met the criteria for cachexia based on weight loss. Weight loss consistent with cachexia occurred over a median period of 220 (IQR: 265) days.

Conclusion: Weight loss in patients with cachexia at NSCLC diagnosis may commence as early as 12 months before cancer diagnosis. Within a year after a cancer diagnosis, more than half of patients develop cachexia, particularly those with advanced disease. These findings support the integration of early nutritional and pharmacological interventions in patients with NSCLC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
130
审稿时长
4-8 weeks
期刊介绍: ​​​​​​​American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信